237 related articles for article (PubMed ID: 24584918)
1. Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial.
Kivitz AJ; Schechtman J; Texter M; Fichtner A; de Longueville M; Chartash EK
J Rheumatol; 2014 Apr; 41(4):648-57. PubMed ID: 24584918
[TBL] [Abstract][Full Text] [Related]
2. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab.
Kaine JL; Kivitz AJ; Birbara C; Luo AY
J Rheumatol; 2007 Feb; 34(2):272-9. PubMed ID: 17304653
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial.
Smolen J; Landewé RB; Mease P; Brzezicki J; Mason D; Luijtens K; van Vollenhoven RF; Kavanaugh A; Schiff M; Burmester GR; Strand V; Vencovsky J; van der Heijde D
Ann Rheum Dis; 2009 Jun; 68(6):797-804. PubMed ID: 19015207
[TBL] [Abstract][Full Text] [Related]
4. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).
Mease PJ; Fleischmann R; Deodhar AA; Wollenhaupt J; Khraishi M; Kielar D; Woltering F; Stach C; Hoepken B; Arledge T; van der Heijde D
Ann Rheum Dis; 2014 Jan; 73(1):48-55. PubMed ID: 23942868
[TBL] [Abstract][Full Text] [Related]
5. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.
Bingham CO; Looney RJ; Deodhar A; Halsey N; Greenwald M; Codding C; Trzaskoma B; Martin F; Agarwal S; Kelman A
Arthritis Rheum; 2010 Jan; 62(1):64-74. PubMed ID: 20039397
[TBL] [Abstract][Full Text] [Related]
6. Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis.
Connock M; Tubeuf S; Malottki K; Uthman A; Round J; Bayliss S; Meads C; Moore D
Health Technol Assess; 2010 Oct; 14(Suppl. 2):1-10. PubMed ID: 21047485
[TBL] [Abstract][Full Text] [Related]
7. Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data.
Curtis JR; Chen L; Luijtens K; Navarro-Millan I; Goel N; Gervitz L; Weinblatt M
Arthritis Rheum; 2011 Aug; 63(8):2203-8. PubMed ID: 21484766
[TBL] [Abstract][Full Text] [Related]
8. Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept.
Alten R; Bingham CO; Cohen SB; Curtis JR; Kelly S; Wong D; Genovese MC
BMC Musculoskelet Disord; 2016 May; 17():231. PubMed ID: 27229685
[TBL] [Abstract][Full Text] [Related]
9. Maintenance therapy with certolizumab pegol for Crohn's disease.
Schreiber S; Khaliq-Kareemi M; Lawrance IC; Thomsen OØ; Hanauer SB; McColm J; Bloomfield R; Sandborn WJ;
N Engl J Med; 2007 Jul; 357(3):239-50. PubMed ID: 17634459
[TBL] [Abstract][Full Text] [Related]
10. Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial.
Strand V; Mease P; Burmester GR; Nikaï E; Coteur G; van Vollenhoven R; Combe B; Keystone EC; Kavanaugh A
Arthritis Res Ther; 2009; 11(6):R170. PubMed ID: 19909548
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.
Landewé R; Braun J; Deodhar A; Dougados M; Maksymowych WP; Mease PJ; Reveille JD; Rudwaleit M; van der Heijde D; Stach C; Hoepken B; Fichtner A; Coteur G; de Longueville M; Sieper J
Ann Rheum Dis; 2014 Jan; 73(1):39-47. PubMed ID: 24013647
[TBL] [Abstract][Full Text] [Related]
12. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Keystone E; Heijde Dv; Mason D; Landewé R; Vollenhoven RV; Combe B; Emery P; Strand V; Mease P; Desai C; Pavelka K
Arthritis Rheum; 2008 Nov; 58(11):3319-29. PubMed ID: 18975346
[TBL] [Abstract][Full Text] [Related]
13. Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis.
Kavanaugh A; Smolen JS; Emery P; Purcaru O; Keystone E; Richard L; Strand V; van Vollenhoven RF
Arthritis Rheum; 2009 Nov; 61(11):1592-600. PubMed ID: 19877104
[TBL] [Abstract][Full Text] [Related]
14. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors.
Kapetanovic MC; Roseman C; Jönsson G; Truedsson L; Saxne T; Geborek P
Arthritis Rheum; 2011 Dec; 63(12):3723-32. PubMed ID: 21834061
[TBL] [Abstract][Full Text] [Related]
15. Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety.
Mease PJ
Rheumatology (Oxford); 2011 Feb; 50(2):261-70. PubMed ID: 20871129
[TBL] [Abstract][Full Text] [Related]
16. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab.
van Assen S; Holvast A; Benne CA; Posthumus MD; van Leeuwen MA; Voskuyl AE; Blom M; Risselada AP; de Haan A; Westra J; Kallenberg CG; Bijl M
Arthritis Rheum; 2010 Jan; 62(1):75-81. PubMed ID: 20039396
[TBL] [Abstract][Full Text] [Related]
17. Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials.
Bykerk VP; Cush J; Winthrop K; Calabrese L; Lortholary O; de Longueville M; van Vollenhoven R; Mariette X
Ann Rheum Dis; 2015 Jan; 74(1):96-103. PubMed ID: 24092417
[TBL] [Abstract][Full Text] [Related]
18. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
[TBL] [Abstract][Full Text] [Related]
19. RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol.
Pincus T; Furer V; Keystone E; Yazici Y; Bergman MJ; Luijtens K
Arthritis Care Res (Hoboken); 2011 Aug; 63(8):1142-9. PubMed ID: 21485024
[TBL] [Abstract][Full Text] [Related]
20. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial.
Sandborn WJ; Schreiber S; Feagan BG; Rutgeerts P; Younes ZH; Bloomfield R; Coteur G; Guzman JP; D'Haens GR
Clin Gastroenterol Hepatol; 2011 Aug; 9(8):670-678.e3. PubMed ID: 21642014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
